Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients
Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients
复制标题
DOI：
10.1097/mbc.0b013e3281067fb2
复制
发表时间：
2007-10-01
影响因子：
1.1
通讯作者：
Tricot, Guido
中科院分区：
文献类型：
--
作者：
Zangari, Maurizio;Barlogie, Bart;Tricot, Guido
静脉血栓栓塞（VTE）是一种与生存率低相关的癌症并发症。我们分析了新诊断的多发性骨髓瘤患者在我们的总治疗方案2中接受了沙利度胺或不使用沙利度胺的化疗后血栓发作的预后影响。在纳入的668例患者中，155例在治疗期间出现静脉血栓栓塞并发症。静脉血栓栓塞患者的总体生存率和无事件生存率并不差。有趣的是，我们观察到，与没有静脉血栓栓塞的患者相比，接受无沙利度胺强化化疗但发生血栓形成的患者的无事件生存期明显更长（P= 0.02）。我们的观察表明抗凝治疗可能对骨髓瘤患者的生存有有益的影响。血液凝血纤维蛋白溶解：595-598 (c) 2007。
Venous thromboembolism (VTE) is a cancer complication associated with poor survival. We have analyzed the prognostic impact of the development of a thrombotic episode in newly diagnosed multiple myeloma patients who received chemotherapy either with or without thalidomide on our Total Therapy 2 protocol. Of 668 patients enrolled, 155 developed VTE complication during treatment. The overall and event-free survival of patients who experienced VTE was not inferior. Of interest, we observed that patients who received intensive chemotherapy without thalidomide but developed a thrombosis experienced a significantly longer event-free survival compared with those without VTE (P= 0.02). Our observation suggests a possible beneficial effect of anticoagulation on survival in patients treated for myeloma. Blood Coagul Fibrinolysis 18:595-598 (c) 2007 Lippincott Williams & Wilkins.